Cargando…

Self-Assembling Peptides as an Emerging Platform for the Treatment of Metabolic Syndrome

Metabolic syndrome comprises a cluster of comorbidities that represent a major risk of developing chronic diseases, such as type II diabetes, cardiovascular diseases, and stroke. Alarmingly, metabolic syndrome reaches epidemic proportions worldwide. Today, lifestyle changes and multiple drug-based t...

Descripción completa

Detalles Bibliográficos
Autores principales: Castillo-Díaz, Luis Alberto, Ruiz-Pacheco, Juan Alberto, Elsawy, Mohamed Ahmed, Reyes-Martínez, Juana Elizabeth, Enríquez-Rodríguez, Andrea Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762440/
https://www.ncbi.nlm.nih.gov/pubmed/33376325
http://dx.doi.org/10.2147/IJN.S278189
_version_ 1783627806226251776
author Castillo-Díaz, Luis Alberto
Ruiz-Pacheco, Juan Alberto
Elsawy, Mohamed Ahmed
Reyes-Martínez, Juana Elizabeth
Enríquez-Rodríguez, Andrea Isabel
author_facet Castillo-Díaz, Luis Alberto
Ruiz-Pacheco, Juan Alberto
Elsawy, Mohamed Ahmed
Reyes-Martínez, Juana Elizabeth
Enríquez-Rodríguez, Andrea Isabel
author_sort Castillo-Díaz, Luis Alberto
collection PubMed
description Metabolic syndrome comprises a cluster of comorbidities that represent a major risk of developing chronic diseases, such as type II diabetes, cardiovascular diseases, and stroke. Alarmingly, metabolic syndrome reaches epidemic proportions worldwide. Today, lifestyle changes and multiple drug-based therapies represent the gold standard to address metabolic syndrome. However, such approaches face two major limitations: complicated drug therapeutic regimes, which in most cases could lead to patient incompliance, and limited drug efficacy. This has encouraged scientists to search for novel routes to deal with metabolic syndrome and related diseases. Within such approaches, self-assembled peptide formulations have emerged as a promising alternative for treating metabolic syndrome. In particular, self-assembled peptide hydrogels, either as acellular or cell-load three-dimensional scaffoldings have reached significant relevance in the biomedical field to prevent and restore euglycemia, as well as for controlling cardiovascular diseases and obesity. This has been possible thanks to the physicochemical tunability of peptides, which are developed from a chemical toolbox of versatile amino acids enabling flexibility of designing a wide range of self-assembled/co-assembled nanostructures forming biocompatible viscoelastic hydrogels. Peptide hydrogels can be combined with several biological entities, such as extracellular matrix proteins, drugs or cells, forming functional biologics with therapeutic ability for treatment of metabolic syndrome-comorbidities. Additionally, self-assembly peptides combine safety, tolerability, and effectivity attributes; by this presenting a promising platform for the development of novel pharmaceuticals capable of addressing unmet therapeutic needs for diabetes, cardiovascular disorders and obesity. In this review, recent advances in developing self-assembly peptide nanostructures tailored for improving treatment of metabolic syndrome and related diseases will be discussed from basic research to preclinical research studies. Challenges facing the development of approved medicinal products based on self-assembling peptide nanomaterials will be discussed in light of regulatory requirement for clinical authorization.
format Online
Article
Text
id pubmed-7762440
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77624402020-12-28 Self-Assembling Peptides as an Emerging Platform for the Treatment of Metabolic Syndrome Castillo-Díaz, Luis Alberto Ruiz-Pacheco, Juan Alberto Elsawy, Mohamed Ahmed Reyes-Martínez, Juana Elizabeth Enríquez-Rodríguez, Andrea Isabel Int J Nanomedicine Review Metabolic syndrome comprises a cluster of comorbidities that represent a major risk of developing chronic diseases, such as type II diabetes, cardiovascular diseases, and stroke. Alarmingly, metabolic syndrome reaches epidemic proportions worldwide. Today, lifestyle changes and multiple drug-based therapies represent the gold standard to address metabolic syndrome. However, such approaches face two major limitations: complicated drug therapeutic regimes, which in most cases could lead to patient incompliance, and limited drug efficacy. This has encouraged scientists to search for novel routes to deal with metabolic syndrome and related diseases. Within such approaches, self-assembled peptide formulations have emerged as a promising alternative for treating metabolic syndrome. In particular, self-assembled peptide hydrogels, either as acellular or cell-load three-dimensional scaffoldings have reached significant relevance in the biomedical field to prevent and restore euglycemia, as well as for controlling cardiovascular diseases and obesity. This has been possible thanks to the physicochemical tunability of peptides, which are developed from a chemical toolbox of versatile amino acids enabling flexibility of designing a wide range of self-assembled/co-assembled nanostructures forming biocompatible viscoelastic hydrogels. Peptide hydrogels can be combined with several biological entities, such as extracellular matrix proteins, drugs or cells, forming functional biologics with therapeutic ability for treatment of metabolic syndrome-comorbidities. Additionally, self-assembly peptides combine safety, tolerability, and effectivity attributes; by this presenting a promising platform for the development of novel pharmaceuticals capable of addressing unmet therapeutic needs for diabetes, cardiovascular disorders and obesity. In this review, recent advances in developing self-assembly peptide nanostructures tailored for improving treatment of metabolic syndrome and related diseases will be discussed from basic research to preclinical research studies. Challenges facing the development of approved medicinal products based on self-assembling peptide nanomaterials will be discussed in light of regulatory requirement for clinical authorization. Dove 2020-12-21 /pmc/articles/PMC7762440/ /pubmed/33376325 http://dx.doi.org/10.2147/IJN.S278189 Text en © 2020 Castillo-Díaz et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Castillo-Díaz, Luis Alberto
Ruiz-Pacheco, Juan Alberto
Elsawy, Mohamed Ahmed
Reyes-Martínez, Juana Elizabeth
Enríquez-Rodríguez, Andrea Isabel
Self-Assembling Peptides as an Emerging Platform for the Treatment of Metabolic Syndrome
title Self-Assembling Peptides as an Emerging Platform for the Treatment of Metabolic Syndrome
title_full Self-Assembling Peptides as an Emerging Platform for the Treatment of Metabolic Syndrome
title_fullStr Self-Assembling Peptides as an Emerging Platform for the Treatment of Metabolic Syndrome
title_full_unstemmed Self-Assembling Peptides as an Emerging Platform for the Treatment of Metabolic Syndrome
title_short Self-Assembling Peptides as an Emerging Platform for the Treatment of Metabolic Syndrome
title_sort self-assembling peptides as an emerging platform for the treatment of metabolic syndrome
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762440/
https://www.ncbi.nlm.nih.gov/pubmed/33376325
http://dx.doi.org/10.2147/IJN.S278189
work_keys_str_mv AT castillodiazluisalberto selfassemblingpeptidesasanemergingplatformforthetreatmentofmetabolicsyndrome
AT ruizpachecojuanalberto selfassemblingpeptidesasanemergingplatformforthetreatmentofmetabolicsyndrome
AT elsawymohamedahmed selfassemblingpeptidesasanemergingplatformforthetreatmentofmetabolicsyndrome
AT reyesmartinezjuanaelizabeth selfassemblingpeptidesasanemergingplatformforthetreatmentofmetabolicsyndrome
AT enriquezrodriguezandreaisabel selfassemblingpeptidesasanemergingplatformforthetreatmentofmetabolicsyndrome